International Childhood Leukemia Microbiome and Metabolome Cohort

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a biobank of clinical data and biological specimens from children diagnosed with acute lymphoblastic leukemia (ALL) to investigate the impact of nutritional status on cancer progression and treatment outcomes. It will include patients aged 3 to 18 years who are newly diagnosed with B- or T-cell ALL or mixed phenotype acute leukemia. The study will focus on understanding how nutrition affects treatment toxicities and survivorship, particularly in low and middle-income countries. Participating centers were selected to represent diverse global health indicators related to nutrition and wealth.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients must be between 3 years and 18 years of age at time of assent/consent.
* Patients must have newly diagnosed B- or T-cell ALL, or mixed phenotype acute leukemia confirmed by pathology report.
* Patients must be receiving treatment at one of the participating centers.

Exclusion Criteria:

\- Patients receiving hematopoietic cell transplant.

Where it's running

• Hospital de Cancer Infanto Juvenil de Barretos
  Barretos, Brazil Recruiting
• Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)
  Recife, Brazil Recruiting
• Instituto de Tratamento do Câncer Infantil (ITACI)
  São Paulo, Brazil Recruiting
• Unidad Nacional De Oncologia Pediatrica
  Guatemala City, Guatemala Recruiting
• Hospital Escuela
  Tegucigalpa, Honduras Recruiting
• Post-Graduate Institute of Medical Education and Research (PGIMER)
  Chandigarh, India Recruiting

Study contacts

• Study coordinator: Elena Ladas, PhD, RD
• Email: ejd14@cumc.columbia.edu
• Phone: +12123057835

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Immunonutrition vs EPA-DHA enriched nutrition for cancer patients having surgery

  This study tests whether immunonutrition or EPA-DHA enriched supplements improve outcomes for cancer patients undergoing surgery.

  Recruiting Maimónides Biomedical Research Institute of Córdoba · Córdoba, Córdoba · NCT07860372

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Observatory of adults with Ph+ ALL receiving BCR-ABL1 inhibitors with chemotherapy, steroids, or monoclonal antibodies

  This study follows adults with Philadelphia-positive acute lymphoblastic leukemia who are being treated with a combination of BCR-ABL1 inhibitors and other therapies to see how they fare in real-world practice.

  Recruiting at 7 sites Versailles Hospital · Amiens and 22 other locations · NCT07684131

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers

  This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.

  Recruiting Phase 1/2 Shenzhen University General Hospital · Shenzhen, Other (Non U.s.) · NCT07584889

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.